FG-2216, soluble in DMSO and insoluble in ethanol and water, is designed to disrupt the hypoxia-inducible factor (HIF) pathway, aiming to hinder cancer cell survival and adaptation in low-oxygen environments characteristic of tumor growth. It targets PHD2.
FG-2216 acts as a HIF inhibitor, employed in research focusing on anemia and ischemic diseases.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.